Serving To Educate Primary Care Clinicians On Metabolic Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Peer-to-peer Exchange Header 3
Metabolic Diseases Header 4
News: Prescriber's Letter October 2015

The new PCSK9 inhibitor, Repatha (rih-PATH-ah, evolocumab), will raise questions about how to help patients stick with a statin.
   Repatha is similar to Praluent (alirocumab).
   Both PCSK9 inhibitors are injectable biologics...may lower LDL about 60%...cost about $14,000/yr...and lack long-term outcome and safety data.
   In general, save these PCSK9 inhibitors as statin add-ons for familial hypercholesterolemia...and not for most other high-risk patients.
   Continue to use target doses of statins to reduce CV risk.
   But be ready to help the up to 30% of statin patients who complain of muscle aches, pain, stiffness, or weakness.

If you would like to access this month's full article on Repatha from Prescriber's letter, please click here

Prescriber's Letter offers PCMG Members a 10% discount at two subscription levels:

The Gold Subscription is $129 and includes CME

The Platinum Subscription is $189 and provides enhanced CME and Live Webinar access 

Enter Discount Code PCMG15 when ordering either subscription HERE